Methylcobalamin (B12)

Best-in-class: Methylcobalamin

The active, methylated form of vitamin B12 used directly in methylation and nerve/blood-cell function — better retained than cheap cyanocobalamin.

How Methylcobalamin (B12) actually works

B12 has exactly two jobs in humans, and they explain the whole symptom picture. As methylcobalamin it's the cofactor for methionine synthase, which converts homocysteine back to methionine — so deficiency raises homocysteine and starves methylation. As adenosylcobalamin it's required by methylmalonyl-CoA mutase, so deficiency raises methylmalonic acid and disrupts myelin maintenance, which is where the numbness and cognitive changes come from. Absorption is the bottleneck: it needs intrinsic factor from the stomach, which is why age, metformin and acid suppression cause deficiency far more often than diet does.

Where to get Methylcobalamin (B12)

The evidence for Methylcobalamin (B12)

Graded by what exists behind each claim.

✅ Clinically validated

• Corrects B12 deficiency (fatigue, neuropathy, anemia) and lowers homocysteine (well-established).
• Supports nerve health and energy metabolism.

📊 Correlative data

• Low B12 is common in older adults, vegans and those on metformin/PPIs, and tracks with fatigue and cognitive decline.

🧪 Theoretical / extrapolated benefits

• Methyl-B12's edge over cyanocobalamin for general outcomes is reasonable but modest in most trials.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Methylcobalamin (B12) actually does

Two enzymes in the whole human body need vitamin B12, and they need two different cobalamins. Methionine synthase, in the cytosol, uses methylcobalamin to transfer a methyl group from 5-methyltetrahydrofolate to homocysteine. Methylmalonyl-CoA mutase, in the mitochondrion, uses adenosylcobalamin to rearrange methylmalonyl-CoA to succinyl-CoA. That is the entire enzymology, and it is why the two functional markers of B12 status are homocysteine and methylmalonic acid: each reports on one of the two enzymes Nexo 2024.

Whatever cobalamin you swallow, the cell strips it back to a common intermediate. Absorbed cobalamins are processed in the cytosol by the MMACHC protein, which dealkylates methylcobalamin and adenosylcobalamin and decyanates cyanocobalamin to give cob(II)alamin. Only then is the cobalt re-alkylated by the specific chaperones that load each enzyme. This is the single most important fact for reading a label: 'active B12' is dismantled before it is used, so the alkyl group on the bottle is not the alkyl group that reaches the enzyme.

Absorption is the most elaborate route any vitamin takes. Salivary haptocorrin binds cobalamin through the stomach; pancreatic proteases release it in the duodenum; intrinsic factor from gastric parietal cells then binds it; the complex is taken up by cubilin and amnionless in the terminal ileum. That system saturates at roughly 1.5 to 2 mcg per meal. Above that, roughly 1 percent of an oral dose crosses by passive diffusion, which is the entire basis for high-dose oral therapy Abdelwahab 2024.

What circulates is mostly not usable, and this is where the surrogate breaks. Cobalamin in plasma is carried on two proteins: haptocorrin, which carries perhaps 70 to 80 percent and delivers to essentially nothing, and transcobalamin, which carries the remaining 20 to 30 percent and is the only form cells can take up through the CD320 receptor. A serum total B12 measures both. Holotranscobalamin measures the fraction that can be used Murphy 2021.

So a normal total B12 is compatible with a cell that is starving for it. If haptocorrin is high — liver disease, myeloid conditions, some cancers — the total looks reassuring while holotranscobalamin and the functional markers say otherwise. That dissociation is the whole reason this page is in a cohort about surrogates.

Cell, rodent, human — and where it stops

The chain here is unusual: the marker fails in BOTH directions, and the outcome literature is mostly about people who did not have a deficiency.

In biochemistry and in cells, none of this is contested. The two enzymes, their cofactors and the processing pathway are settled, and inherited defects in MMACHC and in the transcobalamin receptor produce exactly the metabolic pictures the pathway predicts.

In people, the diagnostic evidence says the common test is the weak one. Comparing holotranscobalamin against total B12 in patients with megaloblastic anemia, the active fraction discriminated better than the total Tufail 2024, and a large real-world evaluation by clinical indication reached a similar conclusion about where each test earns its place Murphy 2021. The current review position is that no single test is adequate and that methylmalonic acid is the functional arbiter Wolffenbuttel 2023 Nexo 2024.

In treatment, route turns out not to matter as much as the injection tradition assumes. A systematic review and network meta-analysis of oral, sublingual, intramuscular and nasal B12 for deficiency found high-dose oral therapy comparable to injection for correcting the biochemistry in most causes of deficiency Abdelwahab 2024. That is a real and useful result, and it is about correcting a deficiency.

Where the transfer breaks is supplementation of people who are not deficient. A systematic review and meta-regression of B12 supplementation for cognitive function, depressive symptoms and fatigue found no consistent benefit in participants without deficiency Markun 2021. The marker rises in everybody. The symptom the product is bought for does not.

And the obstacle is a specific one that gets skipped. Once somebody starts a supplement, both the total B12 and the holotranscobalamin become uninterpretable for the purpose of diagnosing the deficiency they were taken for. The test has to happen first. A great many people arrive at a clinic with a high B12, a supplement in their bag, and a question nobody can now answer.

Methylcobalamin (B12) — which form, and does it matter

Four cobalamins are sold and the differences are real but smaller than the marketing. Cyanocobalamin is the crystalline, cheapest and most stable form and is what almost every trial used. Hydroxocobalamin is the depot form used by injection, with the longest retention. Methylcobalamin and adenosylcobalamin are the two coenzyme forms, both of which are dealkylated intracellularly before use. Stability differs sharply: methylcobalamin is markedly light-sensitive and degrades faster in solution and in some solid matrices than cyanocobalamin does Temova Rakusa 2022.

The cyanide argument is arithmetic, and the arithmetic is small. A 1,000 mcg cyanocobalamin dose releases roughly 20 mcg of cyanide, against a daily dietary intake from ordinary food in the tens to hundreds of micrograms. The exception where it genuinely matters is renal failure, where cyanocobalamin's cyanide is cleared slowly, and hydroxocobalamin is preferred for that reason and in Leber hereditary optic neuropathy.

Sublingual is a route claim that the pharmacokinetics do not support, and it does not matter. Cobalamin is a large, water-soluble corrinoid; buccal absorption of a molecule that size is poor. Sublingual tablets work about as well as swallowed ones because both are relying on the same 1 percent passive diffusion across the gut, which at 1,000 mcg delivers roughly 10 mcg — several times the daily requirement Abdelwahab 2024.

The exposure clock is unusually long and it explains the dosing. Total body stores are 2 to 5 mg, mostly hepatic, against a daily loss of 1 to 3 mcg, so the half-life of the body pool is measured in years and deficiency after gastric surgery or a change to a plant-based diet takes 3 to 5 years to appear. Plasma clearance of a high oral dose is fast — unbound cobalamin above the transcobalamin binding capacity is renally cleared within hours — which is why daily megadoses produce a bright pink urine and a very high serum number rather than proportionally larger stores. There is no first-pass metabolism to speak of and no cytochrome involvement.

What this means for the label in front of the reader. A 1 mg or 5 mg methylcobalamin product is delivering roughly 10 to 50 mcg by diffusion regardless of the alkyl group, and the choice between forms matters most for stability and for renal function, not for activity Temova Rakusa 2022.

What would have to be true, and how you would know it was not

1. Test before treating, because the test stops working afterward. Predict that vitamin B12 rises into or above the reference range within 2 to 4 weeks of any oral product at supplemental dose, and that the rise says nothing about whether a deficiency existed. Draw B12 and methylmalonic acid (MMA) BEFORE the first capsule.

2. Methylmalonic acid is the read-out that decides whether anything was wrong. Predict MMA falls over 4 to 8 weeks in a genuinely deficient person and does not move in a replete one, because MMA reports on the mitochondrial enzyme rather than on the circulating pool Nexo 2024. A high B12 with a persistently high MMA is the pattern that means the supplement is not reaching the enzyme.

3. Homocysteine should fall too, and if it does not, look at folate. Predict homocysteine down within 8 weeks. Because methionine synthase needs both cobalamin and 5-methyltetrahydrofolate, a homocysteine that will not move on adequate B12 points at the folate arm or at renal function rather than at the dose.

4. The prediction that cuts against the product. In an adult with a normal baseline B12 and a normal MMA, predict no improvement in fatigue, mood or cognition at 12 weeks, because the pooled randomized evidence in non-deficient participants shows none Markun 2021. A trial in that population showing benefit would falsify this page.

5. Predict that the active fraction and the total disagree in a predictable direction. Where both are measured, predict holotranscobalamin to identify deficiency that a normal total B12 misses, particularly in older adults and in liver disease Murphy 2021 Tufail 2024. A study showing total B12 to outperform the active fraction against a methylmalonic acid reference standard would overturn the case made here.

What nobody has tested yet

Nobody has established a reference interval for anybody taking a supplement. All the diagnostic thresholds were derived in unsupplemented populations, and a large share of people now presenting for testing are already taking B12. There is no validated way to interpret a serum B12 of 1,200 pg/mL in somebody on 1 mg daily, and that is now the commonest result laboratories see Wolffenbuttel 2023.

The methyl versus cyano question has never had the trial it deserves. A head-to-head randomized comparison of methylcobalamin against cyanocobalamin at equal dose, with methylmalonic acid and holotranscobalamin as endpoints, would settle a decade of marketing in twelve weeks. It has not been run Temova Rakusa 2022.

Nobody knows what tissue concentration a megadose achieves. Serum rises steeply and hepatic stores rise slowly, and the relationship between the two at supraphysiological oral intakes has not been characterized in humans. That gap is why nobody can say whether 5 mg daily is better than 500 mcg daily for anything.

And the observational signal on high B12 is unexplained. Very high serum B12 associates with worse outcomes in several cohorts, almost certainly because haptocorrin rises in liver disease and malignancy rather than because the vitamin is harmful. Nobody has separated the marker from the exposure prospectively, so the honest statement is that the association exists and the causal direction is not established Nexo 2024.

Methylcobalamin (B12) — its own safety story, not its category's

The direct toxicity is close to nil and that is not the risk. There is no tolerable upper intake level for B12 because no adverse effect has been established from high intake in healthy people. Acneiform and rosacea-like eruptions are reported at milligram doses and resolve on stopping.

The risk is diagnostic and it works in two directions. Supplementing before testing erases the ability to diagnose a deficiency, and correcting a deficiency with folate alone leaves the neurological damage progressing while the anemia resolves. Both are errors of sequence rather than of dose Wolffenbuttel 2023.

The causes of deficiency that a supplement does not fix. Pernicious anemia is an autoimmune destruction of parietal cells and needs its own diagnosis and long-term follow-up because of the associated gastric cancer risk. Ileal resection, Crohn's disease and bacterial overgrowth interrupt the absorption step. Nitrous oxide irreversibly oxidizes the cobalt of methylcobalamin and inactivates methionine synthase, which produces a functional deficiency at a normal serum level.

Drugs that lower B12 over years, quietly. Metformin reduces ileal calcium-dependent uptake of the intrinsic factor complex; proton pump inhibitors and H2 blockers reduce the acid and pepsin needed to release cobalamin from food protein. Neither causes a rapid fall, which is exactly why they get missed — the body pool takes years to run down Abdelwahab 2024.

Who needs a clinician rather than a supplement. Anyone with neurological symptoms and a low or borderline B12, because the window for reversing subacute combined degeneration is limited; anyone with a suspected malabsorptive cause; and anyone whose B12 is high without supplementation. Nothing here is medical advice or diagnosis, and these statements have not been evaluated by the Food and Drug Administration.

Sources read for this page

• Wolffenbuttel BH, et al. Vitamin B12. BMJ 2023 · PMID 37984968
• Murphy MJ, et al. Personalising laboratory medicine in the real world: Assessing clinical utility, by clinical indication, of serum total B12 and Active-B12 (holotranscobalamin) in the diagnosis of vitamin B12 deficiency. Annals of Clinical Biochemistry 2021 · PMID 33715445
• Nexo E. Vitamin B12-Related Biomarkers. Food Nutr Bull 2024 · PMID 38987873
• Tufail N. Comparing Holotranscobalamin and Total Vitamin B12 in Diagnosing Vitamin B12 Deficiency in Megaloblastic Anemia Patients. Cureus 2024 · PMID 39529766
• Markun S, et al. Effects of Vitamin B12 Supplementation on Cognitive Function, Depressive Symptoms, and Fatigue: A Systematic Review, Meta-Analysis, and Meta-Regression. Nutrients 2021 · PMID 33809274
• Abdelwahab OA, et al. Efficacy of different routes of vitamin B12 supplementation for the treatment of patients with vitamin B12 deficiency: A systematic review and network meta-analysis. Irish Journal of Medical Science 2024 · PMID 38231320
• Temova Rakusa Z, et al. Vitamin B12 in Foods, Food Supplements, and Medicines: A Review of Its Role and Properties with a Focus on Its Stability. Molecules 2022 · PMID 36615431

How you would know if it worked

Methylcobalamin (B12) — safety & side effects

Bloodwork to run alongside Methylcobalamin (B12)

Baseline first, then again at 8–12 weeks.

The Full Micronutrient Screen panel covers these in one order — 11 markers, $363.60 with the discount applied.

Check results you already have → · All 103 markers A–Z

Methylcobalamin (B12) — frequently asked questions

Methylcobalamin (B12) inside a finished plan

One arm of 4 Protocol Blueprints, free to read in full.

What Methylcobalamin (B12) is used for

Methylcobalamin (B12) appears under 5 goals in the goal router.

Related Vitamins supplements

← Browse the full Supplement Vault

↑ Back to on this page